Ono Pharmaceutical Company, Ltd. Selects Medidata To Power Clinical Trials Exploring Additional Cancer Indications For Immunotherapy Drug OPDIVO (Nivolumab)

NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, announced today that ONO PHARMACEUTICAL CO., LTD. (“ONO”) has expanded its adoption of the Medidata Clinical Cloud® to include all clinical trials testing the use of OPDIVO® (nivolumab) against a broad range of cancers. The Japan-based company will leverage Medidata’s industry-leading electronic data capture and management technology (Medidata Rave®) to evaluate additional indications for OPDIVO, a cutting-edge immunotherapy drug that was initially approved to treat metastatic melanoma.